Latest Wound Care Research from Organogenesis Highlighted at SAWC Fall 2020 Virtual Meeting
Organogenesis Holdings Inc. (Nasdaq: ORGO) announced its participation in the 2020 Symposium on Advanced Wound Care (SAWC), set for November 4-6. Key presentations include a study led by Dr. Oscar M. Alvarez highlighting Apligraf®'s effectiveness in treating pressure injuries. Additionally, the company will sponsor an Innovation Theater event discussing advanced wound care solutions. Attendees can engage with specialists at Organogenesis' virtual booth. The company's COO emphasized its commitment to advancing wound healing standards through evidence-based product offerings.
- Highlighted real-world data on Apligraf® effectiveness in treating pressure injuries from a high-scoring presented study.
- Sponsorship of the Innovation Theater event demonstrates strong industry engagement and visibility.
- Opportunity for direct interaction with tissue regeneration specialists at the company's virtual exhibit.
- None.
CANTON, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that the latest research on its PuraPly® AM, Affinity®, Apligraf®, NuShield® and Dermagraft® product lines will be presented at the 2020 Symposium on Advanced Wound Care (SAWC) Fall Virtual meeting, held November 4-6.
Research highlights include a featured presentation, “Comparative Effectiveness of a Bilayered Living Cellular Construct and a Viable Cryopreserved Placental Membrane for the Treatment of Pressure Injuries,” led by Oscar M. Alvarez, PhD, CCT, FAPWCA, Professor (by Courtesy) at the Department of Surgery, Rutgers New Jersey Medical School. One of the highest scoring abstracts accepted for presentation at SAWC Fall, this presentation will highlight real-world data demonstrating the efficacy of Apligraf® in the treatment of pressure injuries (PRIs).
Attendees can view the presentation during the “Advanced Clinical Practice and Emerging Research” abstract session on November 4 at 3:55 p.m. EST.
As a platinum sponsor of this year’s meeting, Organogenesis will also support the Innovation Theater event, “Innovative Solutions for Addressing Wounds from Head to Toe using PuraPly® AM and Placental Allografts,” moderated by Lee C. Ruotsi, MD, ABWMS, CWS-P, UHM, Medical Director at Saratoga Hospital Center for Wound Healing and Hyperbaric Medicine. The event will feature a panel discussion with leading wound care professionals who will review cases on treating uncommon, hard-to-heal chronic wounds with the Organogenesis product portfolio.
Visitors to the Organogenesis virtual exhibit booth will have the opportunity to live chat with a Tissue Regeneration Specialist and consult with a Medical Science Liaison about Organogenesis’ innovative product solutions.
“By offering a comprehensive product portfolio driven by evidence and clinical data, Organogenesis continues to advance the standard of care in every phase of the wound healing process,” said Patrick Bilbo, Chief Operating Officer at Organogenesis. “We look forward to highlighting our innovative regenerative medicine solutions through an exciting lineup of educational programs and presentations.”
POSTER PRESENTATIONS OF INTEREST INCLUDE:
Dehydrated Placental Allograft (DPA) for the Management of Diabetic Foot Ulcers- A Randomized Controlled
Caporusso JM, Vayser DJ, Cazzell SM, Gorenstein SA, Homsombath B, Sabolinski ML
Effectiveness of a Native Type I Collagen Matrix plus PHMB Antimicrobial in the Treatment of Cutaneous Wounds in a Real World Setting
Gorenstein SA, Bain MA, Oropallo AR, Koullias GJ, Sabolinski ML
Effectiveness of a Native Type I Collagen Matrix plus PHMB Antimicrobial in the Treatment of VLUs in a Real World Setting
Koullias GJ, Bain MA, Sabolinski ML
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts for future events. Forward-looking statements may be identified by the use of words such as “will,” “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” “extend,” “continue” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including Item 1A (Risk Factors) of the Company’s Form 10-K for the year ended December 31, 2019. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis's comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs.
FAQ
What is the significance of Apligraf® in the treatment of pressure injuries presented by Organogenesis?
When is the SAWC virtual meeting in which Organogenesis will participate?
What event is Organogenesis sponsoring at the SAWC?
How can attendees interact with Organogenesis during the SAWC?
